AI-Generated Summary

Sapu Nano has initiated a first-in-human Phase 1 clinical trial for Sapu-003, a novel intravenous (IV) Deciparticle™ formulation of everolimus, an mTOR inhibitor. This study, presented at ATBCR 2025, aims to overcome the bioavailability and toxicity limitations of oral everolimus in advanced HR+/HER2– breast cancer and other mTOR-sensitive tumors. The development leverages strategic partnerships for robust clinical execution, representing a significant advance in targeted oncology therapies.

In a nutshell

This trial marks a crucial step in advancing targeted cancer therapies by addressing current limitations of a widely used drug. Its success could broaden the therapeutic utility of everolimus and validate Sapu Nano's Deciparticle™ technology for future drug delivery innovations.

Source: GlobeNewswire